Clinical effect of enoxaparin on international normalized ratio following hepato‐pancreatico‐biliary and gastroesophageal resection

Kelecy, Matthew W.; Shutt, Travis; Rostas, Jack W.; Martin, Robert C.G.

doi:10.1002/jso.25113

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, enoxaparin needs to be monitored for anti-Xa levels to guarantee proper anticoagulation, as due to its mechanism of action (inactivates Factor Xa using a complex formed with anti-thrombin III) it cannot be monitored by PT and aPTT. 28 To prevent the common side effect of bleeding 29 anti-Xa is regarded as the gold standard for monitoring enoxaparin. 30 …”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis

Awan,

Ahmad,

Daniyal

et al. 2024

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Objective To examine the effectiveness of rivaroxaban compared to enoxaparin in patients diagnosed with cancer and venous thromboembolism. Methods A search of Pub Med, Scopus, and Google Scholar, from inception through April 2023 was conducted. Articles comparing rivaroxaban with enoxaparin in patients with cancer and VTE/PE/DVT were included. Review Manager Version 5.2 was utilised for the analysis of the following outcomes; VTE, PE, DVT, major bleeding, and mortality. Results A total of 8 articles and 2276 patients were included in the final analysis. Pooled analysis showed that rivaroxaban had a statistically insignificant reduced association with VTE occurrence (RR:0.83, 95% CI:0.58–1.18, P:0.3) as well as a statically insignificant reduction in major bleeding (RR:0.79, 95% CI:0.53–1.18, P:0.25). Analysis showcased that there was an insignificant reduction of mortality rivaroxaban as compared to enoxaparin (RR:0.74, 95% CI: 0.46–1.20, P:0.23). Conclusion Rivaroxaban can serve as a viable alternative to enoxaparin, with no appreciable drawbacks, for preventing and managing VTE in patients with malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis

Awan,

Ahmad,

Daniyal

et al. 2024

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

Major bleeding under enoxaparin treatment. An unexpected second offender

Naschitz¹

2021

MOJCR

View full text Add to dashboard Cite

Admitted to hospital with an ischemic stroke, a 63-year-old male was diagnosed with a left ventricular mural thrombus. Enoxaparin treatment was started. Over 6 weeks there were two episodes of major hemorrhage needing brief discontinuation of anticoagulation. A previously normal prothrombin time (PT) became prolonged upon which vitamin K deficiency was diagnosed. The deficiency was caused by enteral feeding using a formula which did not contain the required daily dose of vitamin K. A triple message emerges from this observation: theneed for monitoring the PT in patients receiving enteral feeding, more so in those receiving anticoagulant along with enteral feeding, and the appeal to fortify feeding formulas with vitamin K.

show abstract

Clinical effect of enoxaparin on international normalized ratio following hepato‐pancreatico‐biliary and gastroesophageal resection

Abstract: This is the first clinical evidence of the effect of enoxaparin on INR in patients undergoing abdominal surgeries for malignancies. We demonstrate an increase in the INR for patients who received enoxaparin for post-operative VTE prophylaxis.

Cited by 2 publications

References 13 publications

Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis

Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis

Major bleeding under enoxaparin treatment. An unexpected second offender

Contact Info

Product

Resources

About